Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.

Psychiatr Serv. 2007 Apr;58(4):489-95.

2.

Treatment of schizoaffective disorder and schizophrenia with mood symptoms.

Levinson DF, Umapathy C, Musthaq M.

Am J Psychiatry. 1999 Aug;156(8):1138-48. Review.

PMID:
10450252
3.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
4.
5.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

6.

Polypharmacy in schizophrenia.

Zink M, Englisch S, Meyer-Lindenberg A.

Curr Opin Psychiatry. 2010 Mar;23(2):103-11. doi: 10.1097/YCO.0b013e3283366427. Review.

PMID:
20051861
7.

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Barnes TR, Paton C.

CNS Drugs. 2011 May;25(5):383-99. doi: 10.2165/11587810-000000000-00000. Review.

PMID:
21476610
8.

CE: Antipsychotic Medications.

Sabella D.

Am J Nurs. 2017 Jun;117(6):36-43. doi: 10.1097/01.NAJ.0000520229.04987.46. Review.

PMID:
28504976
9.

Schizoaffective disorder: a review of current research themes and pharmacological management.

Kantrowitz JT, Citrome L.

CNS Drugs. 2011 Apr;25(4):317-31. doi: 10.2165/11587630-000000000-00000. Review.

PMID:
21284405
10.

Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness.

Westaway K, Sluggett JK, Alderman C, Procter N, Roughead E.

Int J Evid Based Healthc. 2016 Sep;14(3):104-12. doi: 10.1097/XEB.0000000000000082. Review.

PMID:
27213238
11.

When is antipsychotic polypharmacy supported by research evidence? Implications for QI.

Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann RC.

Jt Comm J Qual Patient Saf. 2008 Oct;34(10):571-82. Review.

PMID:
18947117
12.

A tipping point in drug dosing in late-life schizophrenia.

Tsuboi T, Suzuki T, Uchida H.

Curr Psychiatry Rep. 2011 Jun;13(3):225-33. doi: 10.1007/s11920-011-0189-z. Review.

PMID:
21327902
13.

Sensitivity to antipsychotic drugs in older adults.

Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC.

Curr Psychiatry Rep. 2010 Feb;12(1):28-33. doi: 10.1007/s11920-009-0080-3. Review.

PMID:
20425307
14.

Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D.

Br J Psychiatry. 2016 Nov;209(5):361-365. Review.

15.

[Psychobiological significance of antipsychotics in multi-high dose drug therapy for schizophrenia].

Watanabe K.

Seishin Shinkeigaku Zasshi. 2006;108(6):608-13. Review. Japanese.

PMID:
16910538
16.

Psychosis and seizure disorder: challenges in diagnosis and treatment.

Roy K, Balon R, Penumetcha V, Levine BH.

Curr Psychiatry Rep. 2014 Nov;16(11):509. doi: 10.1007/s11920-014-0509-1. Review.

PMID:
25234075
17.

Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system.

Kahl KG, Westhoff-Bleck M, Krüger THC.

Vascul Pharmacol. 2017 Sep 6. pii: S1537-1891(17)30172-6. doi: 10.1016/j.vph.2017.09.001. [Epub ahead of print] Review.

PMID:
28888918
18.

Antipsychotic-induced hyperprolactinaemia: case studies and review.

Mittal S, Prasad S, Ghosh A.

Postgrad Med J. 2017 Nov 9. pii: postgradmedj-2017-135221. doi: 10.1136/postgradmedj-2017-135221. [Epub ahead of print] Review.

PMID:
29122927

Supplemental Content

Support Center